Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group LimitedfiledCriticalGlaxo Group Limited
Priority claimed from PCT/EP2002/012482external-prioritypatent/WO2003041722A1/en
Publication of HK1070561A1publicationCriticalpatent/HK1070561A1/zh
Publication of HK1070561BpublicationCriticalpatent/HK1070561B/zh
Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Report from the second Mount Sinai-New York University Reperfusion Trial.
Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate
Anvendelse af AICA-ribosid eller AICA-ribotid til fremstilling af et farmaceutisk præparat til behandling af hjerteanfald eller salgtilfælde i patienter, som lider af atherosklerose
HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte
Dawka pentasacharydu metylo-O-(2,3,4-tri-O-metylo-6-O-sulfo-α-D-glukopiranozylo)-(1→4)-O-(2,3-di-O-metylo-β-D-glukopiranozylo kwas uronowy)-(1→4)-O-(2,3,6-tri-O-sulfo-α-D-glukopiranozylo)-(1→4)-O-(2,3-di-O-metylo-α-L-idopiranozylo kwas uronowy)-(1→4)-2,3,6-tri-O-sulfo-α-D-glukopiranozydu i jej zastosowanie
An interim report of a double-blind placebo-controlled recanalisation study of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction